{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,13]],"date-time":"2026-09-13T23:03:17Z","timestamp":1789340597924,"version":"build-2803163510"},"reference-count":12,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,9,13]]},"DOI":"10.7759\/cureus.116188","type":"journal-article","created":{"date-parts":[[2026,9,13]],"date-time":"2026-09-13T22:13:30Z","timestamp":1789337610000},"source":"Crossref","is-referenced-by-count":0,"title":["Triple Renal Pathology in a Patient With Myeloperoxidase-Associated Vasculitis, Diabetic Nephropathy, and Immunoglobulin A Nephropathy: A Case Report"],"prefix":"10.7759","author":[{"given":"Riddhi","family":"Patel","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yash","family":"Patel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Supritha","family":"Sakhamuri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akilandanayaki","family":"Angamuthu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0909905","article-title":"Rituximab versus cyclophosphamide for ANCA-associated vasculitis","volume":"363","author":"Stone JH","year":"2010","unstructured":"Stone JH, Merkel PA, Spiera R, et al.. Rituximab versus cyclophosphamide for ANCA-associated vasculitis. N Engl J Med. 2010, 363:221-32. 10.1056\/NEJMoa0909905","journal-title":"N Engl J Med"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1155\/2022\/2032525","article-title":"Triple jeopardy: rapidly progressive glomerulonephritis induced by triple seropositive disease - a rare case","volume":"2022","author":"Vedire A","year":"2022","unstructured":"Vedire A, Upadrasta G, Udongwo N, Rehman F, Hossain MA. Triple jeopardy: rapidly progressive glomerulonephritis induced by triple seropositive disease - a rare case. Case Rep Med. 2022, 2022:10.1155\/2022\/2032525","journal-title":"Case Rep Med"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.2215\/CJN.11491116","article-title":"Diabetic kidney disease: challenges, progress, and possibilities","volume":"12","author":"Alicic RZ","year":"2017","unstructured":"Alicic RZ, Rooney MT, Tuttle KR. Diabetic kidney disease: challenges, progress, and possibilities. Clin J Am Soc Nephrol. 2017, 12:2032-45. 10.2215\/CJN.11491116","journal-title":"Clin J Am Soc Nephrol"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.5455\/medarh.2019.73.87-91","article-title":"Non-diabetic kidney disease in patients with type 2 diabetes mellitus - 11-year experience from a single center","volume":"73","author":"Grujicic M","year":"2019","unstructured":"Grujicic M, Salapura A, Basta-Jovanovic G, Figurek A, Micic-Zrnic D, Grbic A. Non-diabetic kidney disease in patients with type 2 diabetes mellitus - 11-year experience from a single center. Med Arch. 2019, 73:87-91. 10.5455\/medarh.2019.73.87-91","journal-title":"Med Arch"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.49598","article-title":"Overlap of primary membranous nephropathy, IgA nephropathy, and diabetic nephropathy: a case report","volume":"15","author":"Alghamdi AH","year":"2023","unstructured":"Alghamdi AH. Overlap of primary membranous nephropathy, IgA nephropathy, and diabetic nephropathy: a case report. Cureus. 2023, 15:10.7759\/cureus.49598","journal-title":"Cureus"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1155\/2021\/1497449","article-title":"Diabetic nephropathy: challenges in pathogenesis, diagnosis, and treatment","volume":"2021","author":"Samsu N","year":"2021","unstructured":"Samsu N. Diabetic nephropathy: challenges in pathogenesis, diagnosis, and treatment. Biomed Res Int. 2021, 2021:10.1155\/2021\/1497449","journal-title":"Biomed Res Int"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1404231","article-title":"Rituximab versus azathioprine for maintenance in ANCA-associated vasculitis","volume":"371","author":"Guillevin L","year":"2014","unstructured":"Guillevin L, Pagnoux C, Karras A, et al.. Rituximab versus azathioprine for maintenance in ANCA-associated vasculitis. N Engl J Med. 2014, 371:1771-80. 10.1056\/NEJMoa1404231","journal-title":"N Engl J Med"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.2215\/CJN.10550620","article-title":"PEXIVAS: the end of plasmapheresis for ANCA-associated vasculitis?","volume":"16","author":"De Vriese AS","year":"2021","unstructured":"De Vriese AS, Fervenza FC. PEXIVAS: the end of plasmapheresis for ANCA-associated vasculitis?. Clin J Am Soc Nephrol. 2021, 16:307-9. 10.2215\/CJN.10550620","journal-title":"Clin J Am Soc Nephrol"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1016\/j.kint.2023.10.008","article-title":"KDIGO 2024 clinical practice guideline for the management of antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis","volume":"105","author":"Kidney Disease: Improving Global Outcomes (KDIGO) ANCA Vasculitis Work Group","year":"2024","unstructured":"Kidney Disease. Improving Global Outcomes (KDIGO) ANCA Vasculitis Work Group: KDIGO 2024 clinical practice guideline for the management of antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis. Kidney Int. 2024, 105:71-116. 10.1016\/j.kint.2023.10.008","journal-title":"Kidney Int"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1803537","article-title":"Plasma exchange and glucocorticoids in severe ANCA-associated vasculitis","volume":"382","author":"Walsh M","year":"2020","unstructured":"Walsh M, Merkel PA, Peh CA, et al.. Plasma exchange and glucocorticoids in severe ANCA-associated vasculitis. N Engl J Med. 2020, 382:622-31. 10.1056\/NEJMoa1803537","journal-title":"N Engl J Med"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2024816","article-title":"Dapagliflozin in patients with chronic kidney disease","volume":"383","author":"Heerspink HJ","year":"2020","unstructured":"Heerspink HJ, Stef\u00e1nsson BV, Correa-Rotter R, et al.. Dapagliflozin in patients with chronic kidney disease. N Engl J Med. 2020, 383:1436-46. 10.1056\/NEJMoa2024816","journal-title":"N Engl J Med"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1016\/j.kint.2021.03.033","article-title":"A pre-specified analysis of the DAPA-CKD trial demonstrates the effects of dapagliflozin on major adverse kidney events in patients with IgA nephropathy","volume":"100","author":"Wheeler DC","year":"2021","unstructured":"Wheeler DC, Toto RD, Stef\u00e1nsson BV, et al.. A pre-specified analysis of the DAPA-CKD trial demonstrates the effects of dapagliflozin on major adverse kidney events in patients with IgA nephropathy. Kidney Int. 2021, 100:215-24. 10.1016\/j.kint.2021.03.033","journal-title":"Kidney Int"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/529628-triple-renal-pathology-in-a-patient-with-myeloperoxidase-associated-vasculitis-diabetic-nephropathy-and-immunoglobulin-a-nephropathy-a-case-report","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,13]],"date-time":"2026-09-13T22:13:31Z","timestamp":1789337611000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/529628-triple-renal-pathology-in-a-patient-with-myeloperoxidase-associated-vasculitis-diabetic-nephropathy-and-immunoglobulin-a-nephropathy-a-case-report"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,13]]},"references-count":12,"URL":"https:\/\/doi.org\/10.7759\/cureus.116188","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9,13]]}}}